Zinger Key Points
- Jim Cramer shifts his stance on Northrop Grumman, giving it a thumbs up at current prices.
- John Bean Technologies gets a nod from Cramer as a 'quirky but good' investment option.
- AMC's struggle to attract moviegoers prompts Cramer to advise investors to look elsewhere.
- Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to track all 535 Congress member stock trades today.
In a recent episode of CNBC’s “Mad Money,” host Jim Cramer discouraged viewers from investing in AMC Entertainment Holdings Inc. AMC stock, citing the company’s recent performance. Instead, he recommended two other stocks.
What Happened: Cramer, in his “Lightning Round” segment, expressed his reservations about AMC’s stock on Monday, as reported by CNBC on Monday. He suggested that the company’s stock isn’t performing well, attributing this to a decline in moviegoers.
"We don't want AMC. AMC's not doing well. We want stocks that go higher…The consumer's not going to the movies like they used to."
He advised viewers to consider investing in Northrop Grumman Corporation NOC and John Bean Technologies Corporation JBT instead. Cramer, who had previously been hesitant about Northrop Grumman, said he was now ready to “pull the trigger” at the current price of $438.
See Also: Forget GameStop Stock, Now There’s A GameStop Memecoin And It’s Worth Millions
He also expressed his fondness for John Bean Technologies, a company in the global industrial food sector, calling it “a little quirky, but good.”
Why It Matters: AMC has been a subject of intense market speculation and short interest. AMC’s short percent of float increased by 3.51% in a recent report. The company has 24.10 million shares sold short, which is 9.74% of all regular shares available for trading. This indicates a bearish market sentiment towards the stock.
Despite a 45.2% year-over-year increase in third-quarter revenue, AMC’s recovery post-pandemic has been a subject of debate. In November, Benchmark analyst Mike Hickey reiterated a Hold rating on the stock, suggesting a wait-and-see approach to its innovative recovery path.
Photo via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.